Secretory carcinoma of the major salivary gland: Provincial population‐based analysis of clinical behavior and outcomes. Issue 5 (28th December 2018)

• Record Type: Journal Article
• Authors: Ayre, Gareth; Hyrcza, Martin; Wu, Jonn; Berthelet, Eric; Skálová, Alena; Thomson, Tom
• Is Part Of: Head & neck. Volume 41:Issue 5(2019)
• Page Start: 1227
• Page End: 1236
• Publication Date: 2018-12-28
• Subjects: ETV6 -- head and neck surgery -- mammary analog secretory carcinoma -- MASC -- salivary gland tumors; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25536
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Our aim was to identify the number of cases of secretory carcinoma (SC) of the major salivary gland in a population‐based cohort and review its clinical behavior with long‐term follow‐up. Methods: All malignant salivary gland tumors (MSGTs) diagnosed between 1980 and 2014 were assessed for histological features compatible with SC and 140 were selected for further analysis. Results: Twenty two new cases of SC were identified, 19 of which were originally classified as acinic cell carcinoma, and 3 as adenocarcinoma, not otherwise specified (NOS). Lymph node involvement was less common in SC tumors (5%) than in the control group (11%). Disease recurrence was seen less frequently in SC (9%) than the control group (20%). Mean disease‐free survival was 192 months for SC compared with 162 months for controls ( P = 0.15). Conclusion: The clinical course of SC is typically indolent with a low risk of relapse not significantly different from other low‐grade MSGT.